George Clinical
Science. Service. Solutions.
 
  • About Us
    • George Clinical
    • Clinical Trial Excellence
      • Early Phase Research (Phase I-II)
      • Late Phase Research
    • Site Networks and Patient Recruitment
    • Management Team
    • Therapeutic Leadership Team
    • Board of Directors
    • Corporate News
  • Scientific Leaders
    • Our Scientific Leaders
    • Scientific Leadership Spotlight
      • David Thomas
      • Chee Kay Cheung
      • Herbert H. F. Loong
      • Hernan Trimarchi
      • Mustafa Khasraw
      • Ralph Boccia
      • Sradha Kotwal
      • Muh Geot Wong
      • Roberto Pecoits-Filho
  • Services
    • Clinical Research Services
    • Medical Writing
    • Health Economics
    • Statistics Services
    • Endpoint Adjudication
    • Quality Management
    • Medical Monitoring
    • Safety & Pharmacovigilance Services
    • Data Management
    • Project Management
    • Program and Protocol Design
    • Scientific Leadership
    • Clinical Monitoring and Site Management
    • Regulatory Services
    • Real World Evidence (RWE) Research and Observational Trials
  • Therapeutic Expertise
    • Areas of Therapeutic Expertise
    • Kidney & Metabolic
      • Global Kidney Patients Trials Network (GKPTN)
    • Oncology
    • Cardiovascular
    • Neuroscience
    • Respiratory
    • Endocrinology
    • Medical Devices
  • Global Locations
    • George Clinical Worldwide Locations
    • Australia
    • China
    • Hong Kong
    • India
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • United States
    • Europe
  • Case Studies
    • George Clinical Case Studies
  • News & Events
    • Latest News
    • Events
    • Video Library
  • RFP/RFI
  • Contact Us
    • Office Locations and Phone Numbers
    • Register as a Research Professional
    • Careers

Benefits of DPPIV-inhibitors still uncertain

  • By George Clinical
  • June 21st, 2016
  • Posted In:
  • Tags: cardiovascular disease, diabetes, DPPIV, Regulatory services, renal, Scientific Leadership, Vlado Perkovic